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OBJECTIVES: Mucopolysaccharidosis II (MPS II; Hunter syn-
drome) is a rare lysosomal storage disorder that leads to severe
functional declines in childhood and adolescence. Because no
disease-speciﬁc instruments currently exist for MPS II, this study
sought to conﬁrm the previously established psychometric prop-
erties of the CHAQ in this disease population. METHODS: All
twelve families participating in a Phase I/II enzyme replacement
therapy trial for MPS II agreed to participate in the IRB-
approved CHAQ conﬁrmatory validation study. Assessments
were completed during regular twice-monthly study visits. Only
patients 12 years and older completed the instrument although
all parents were asked to complete the questionnaire as a proxy
responder. Face validity, internal reliability, domain intercorrela-
tion coefﬁcients, parent-child correlations, and test-retest relia-
bility were assessed on the overall CHAQ disability index.
RESULTS: Nine patients (mean age 18.0 ± 4.3 years) and one
parent per child completed the CHAQ; three additional patients
(mean age 9.7 ± 1.5 years) had parent-reported assessments only
due to age limitations. The instrument showed good internal reli-
ability (Cronbach’s alpha = 0.86 [parents] and 0.83 [patients])
and good reproducibility in a test-retest over a 3-week period
(Spearman correlation coefﬁcient = 0.81, p = 0.0014 [parent];
0.94, p = 0.0002 [patient]). Parent-child correlation was moder-
ately weak at 0.38 (p = 0.317), a divergence commonly seen in
child/adolescent outcome measurements. Intercorrelation coefﬁ-
cients of each domain with the overall disability index were in
the moderate range (mean rs = 0.6 for parents, rs = 0.5 for
patient). Although face validity was acceptable, the CHAQ still
did not completely address certain functional challenges speciﬁc
to MPS II. CONCLUSION: The psychometric properties of the
CHAQ appear acceptable in measuring general disability and
functional status in MPS II. Further assessment of its sensitivity
and discriminant validity are needed as part of ongoing clinical
trials. Development of a disease-speciﬁc instrument appears war-
ranted given the unique functional challenges of patients with
MPS II.
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OBJECTIVES: To develop and pilot-test a new instrument to
assess physical functioning in children with Mucopolysacchari-
dosis II (MPS II; Hunter syndrome [HS]), a rare genetic, lysoso-
mal storage disease. METHODS: The survey item pool was
generated by: 1) thorough literature review to identify relevant
domains and questions; 2) consultation with expert clinicians
knowledgeable about MPS II; 3) identiﬁcation of indicators spe-
ciﬁc to MPS II not covered by existing instruments, and 4) input
from families affected by MPS II. Following IRB approval, the
item pool was tested in MPS II patients and their families attend-
ing the 2003 Annual MPS Society Family Conference. Data were
obtained via structured feedback forms completed during face-
to-face interviews. Inter-item correlations within each domain
were tested for internal reliability. Results were used to modify
items to create a ﬁnalized instrument, the HS-FOCUS.
RESULTS: Two versions of the HS-FOCUS were created. The
parent-reported form included 59 items and the patient-reported
form included 58 items, in the domains of standing/walking,
grip/reach, sleeping, schooling, activities, eating/appetite, satis-
faction and botheredness with functional status, and treatment
satisfaction. Sixteen parents and 2 adult MPS II patients com-
pleted the questionnaire and provided feedback on relevance of
questions, understandability, and feasibility of use. Domains of
grip/reach, schooling, activities, satisfaction, and botheredness
with physical function achieved a Cronbach’s alpha of at least
0.84. Based on these analyses for construct validity along with
written and interview feedback, 16 items were revised for clarity
and speciﬁcity, 6 were removed, and 9 were added. CONCLU-
SIONS: Preliminary results suggest that the HS-FOCUS may be
useful for assessing functional health in MPS II. Inasmuch as
existing instruments do not adequately assess functional out-
comes in patients with MPS II, this preliminary version of the
HS-FOCUS may offer clinicians and researchers an opportunity
to do so. Future studies should validate the instrument.
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OBJECTIVES: To validate a new instrument, the Hunter 
Syndrome-Functional Outcomes for Clinical Understanding
Scale (HS-FOCUS), a new instrument for assessing functional
status in children and adolescents with Mucopolysaccharidosis
II (MPS II; Hunter syndrome [HS]), one of a group of rare
genetic, lysosomal storage diseases. METHODS: Following IRB
approval, participants were recruited from the 2003 Annual
MPS Family Conference and an ongoing MPS II Phase I/II clin-
ical trial. Eligible participants were individuals with MPS II at
least 12 years old or a parent of a child of any age with MPS II.
The instrument was administered twice over a 3-week period.
Face validity, internal reliability, domain intercorrelation, parent-
child correlations, and test-retest reliability were assessed for
each of six domains (standing/walking, grip/reach, sleeping,
schooling/work, activities, and breathing) and for the overall dis-
ability score. RESULTS: Eleven patients with MPS II and 27
parent caregivers of patients with MPS II completed the HS-
FOCUS. Face validity was conﬁrmed through interviews with
expert clinicians, patients with MPS II, and their families. The
instrument showed very good overall internal reliability (Cron-
bach’s alpha = 0.93 [parents] and 0.83 [patients]). The HS-
FOCUS showed good reproducibility (rs = 0.85, p < 0.0001
[parents] and 0.71, p = 0.031 [patients)] for overall function in
test-retest analyses, although sleeping and breathing domains
had weaker correlations. Intercorrelation coefﬁcients for each
domain with the overall functional disability score were strong
(range rs = 0.69 to 0.89). Weak correlations were reported
between the nine parent-child pairs, which is commonly accepted
as a challenge in survey research of children and adolescents.
CONCLUSIONS: Findings of this validation study suggest that
the HS-FOCUS may effectively capture disability and functional
status in individuals with MPS II. Additional assessment of sen-
